Immunocore Holdings PLC
NASDAQ:IMCR
Intrinsic Value
Immunocore Holdings Plc operates as a holding company. [ Read More ]
The intrinsic value of one IMCR stock under the Base Case scenario is 95.82 USD. Compared to the current market price of 58.47 USD, Immunocore Holdings PLC is Undervalued by 39%.
Valuation Backtest
Immunocore Holdings PLC
Run backtest to discover the historical profit from buying and selling IMCR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Immunocore Holdings PLC
Current Assets | 528.8m |
Cash & Short-Term Investments | 442.6m |
Receivables | 52.1m |
Other Current Assets | 34.1m |
Non-Current Assets | 68.2m |
Long-Term Investments | 14.5m |
PP&E | 42.7m |
Other Non-Current Assets | 11m |
Current Liabilities | 139m |
Accounts Payable | 17.8m |
Accrued Liabilities | 121.2m |
Non-Current Liabilities | 89.1m |
Long-Term Debt | 48m |
Other Non-Current Liabilities | 41.1m |
Earnings Waterfall
Immunocore Holdings PLC
Revenue
|
249.4m
GBP
|
Cost of Revenue
|
-1m
GBP
|
Gross Profit
|
248.4m
GBP
|
Operating Expenses
|
-308m
GBP
|
Operating Income
|
-59.6m
GBP
|
Other Expenses
|
4.4m
GBP
|
Net Income
|
-55.3m
GBP
|
Free Cash Flow Analysis
Immunocore Holdings PLC
IMCR Profitability Score
Profitability Due Diligence
Immunocore Holdings PLC's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Immunocore Holdings PLC's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
IMCR Solvency Score
Solvency Due Diligence
Immunocore Holdings PLC's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Immunocore Holdings PLC's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMCR Price Targets Summary
Immunocore Holdings PLC
According to Wall Street analysts, the average 1-year price target for IMCR is 87.11 USD with a low forecast of 63.63 USD and a high forecast of 96.6 USD.
Ownership
IMCR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IMCR Price
Immunocore Holdings PLC
Average Annual Return | 46.75% |
Standard Deviation of Annual Returns | 21.03% |
Max Drawdown | -66% |
Market Capitalization | 2.9B USD |
Shares Outstanding | 49 820 600 |
Percentage of Shares Shorted | 10.43% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.
Contact
IPO
Employees
Officers
The intrinsic value of one IMCR stock under the Base Case scenario is 95.82 USD.
Compared to the current market price of 58.47 USD, Immunocore Holdings PLC is Undervalued by 39%.